O	0	12	Satisfaction
O	13	17	with
O	18	22	care
O	23	26	and
O	27	36	adherence
O	37	39	to
O	40	49	treatment
O	50	54	when
O	55	60	using
O	61	68	patient
O	69	77	reported
O	78	86	outcomes
O	87	89	to
O	90	103	individualize
O	104	110	follow
O	110	111	-
O	111	113	up
O	114	118	care
O	119	122	for
O	123	128	women
O	129	133	with
O	134	139	early
O	140	146	breast
O	147	153	cancer
O	154	155	-
O	156	157	a
O	158	163	pilot
O	164	174	randomized
O	175	185	controlled
O	186	191	trial
O	191	192	.

O	193	203	Background
O	203	204	:
O	205	208	The
O	209	219	population
O	220	222	of
O	223	229	breast
O	230	236	cancer
O	237	246	survivors
O	247	249	is
O	250	260	increasing
O	261	263	as
O	264	265	a
O	266	274	positive
O	275	286	consequence
O	287	289	of
O	290	295	early
O	296	305	detection
O	306	309	and
O	310	318	enhanced
O	319	328	treatment
O	328	329	.

O	330	333	The
O	334	341	disease
O	342	345	and
O	346	355	treatment
O	356	366	associated
O	367	371	side
O	371	372	-
O	372	379	effects
O	380	382	or
O	383	387	late
O	387	388	-
O	388	395	effects
O	396	401	often
O	402	408	impact
O	409	411	on
O	412	419	quality
O	420	422	of
O	423	427	life
O	428	431	and
O	432	437	daily
O	438	442	life
O	443	452	functions
O	453	459	during
O	460	472	survivorship
O	472	473	.

O	474	478	This
O	479	484	calls
O	485	488	for
O	489	501	optimization
O	502	504	of
O	505	511	follow
O	511	512	-
O	512	514	up
O	515	519	care
O	519	520	.

O	521	523	We
O	524	529	aimed
O	530	532	to
O	533	541	evaluate
O	542	545	the
O	546	554	patients
O	554	555	'
O	556	568	satisfaction
O	569	573	with
O	574	577	the
O	578	582	care
O	583	591	provided
O	591	592	,
O	593	597	when
O	598	603	using
O	604	614	electronic
O	615	622	patient
O	623	631	reported
O	632	640	outcomes
O	641	642	(
O	642	647	ePROs
O	647	648	)
O	649	651	to
O	652	665	individualize
O	666	672	follow
O	672	673	-
O	673	675	up
O	676	680	care
O	681	683	in
O	684	689	women
O	690	694	with
O	695	700	early
O	701	707	breast
O	708	714	cancer
O	715	724	receiving
O	725	733	adjuvant
O	734	743	endocrine
O	744	751	therapy
O	751	752	.

O	753	761	Material
O	762	765	and
O	766	773	methods
O	773	774	:
B-eligibility	775	789	Postmenopausal
I-eligibility	790	795	women
I-eligibility	796	803	treated
I-eligibility	804	807	for
I-eligibility	808	815	hormone
I-eligibility	816	824	receptor
I-eligibility	825	833	positive
I-eligibility	834	839	early
I-eligibility	840	846	breast
I-eligibility	847	853	cancer
O	854	858	were
O	859	867	included
O	868	870	in
O	871	872	a
O	873	878	pilot
O	879	889	randomized
O	890	900	controlled
O	901	906	trial
O	907	910	and
O	911	921	randomized
O	922	924	to
O	925	932	receive
B-control	933	941	standard
I-control	942	948	follow
I-control	948	949	-
I-control	949	951	up
I-control	952	956	care
O	957	961	with
O	962	974	prescheduled
O	975	988	consultations
O	989	994	every
O	995	998	six
O	999	1005	months
O	1006	1008	or
B-intervention	1009	1023	individualized
I-intervention	1024	1030	follow
I-intervention	1030	1031	-
I-intervention	1031	1033	up
I-intervention	1034	1038	care
O	1039	1043	with
O	1044	1047	the
O	1048	1054	active
O	1055	1058	use
O	1059	1061	of
O	1062	1067	ePROs
O	1068	1070	to
O	1071	1077	screen
O	1078	1081	for
O	1082	1085	the
O	1086	1090	need
O	1091	1093	of
O	1094	1107	consultations
O	1107	1108	.

O	1109	1114	ePROs
O	1115	1119	were
O	1120	1131	distributed
O	1132	1137	every
O	1138	1143	third
O	1144	1149	month
O	1150	1154	over
O	1155	1156	a
O	1157	1160	two
O	1160	1161	-
O	1161	1165	year
O	1166	1172	period
O	1172	1173	.

O	1174	1181	Primary
O	1182	1190	outcomes
O	1191	1195	were
B-outcome-Measure	1196	1208	satisfaction
I-outcome-Measure	1209	1213	with
I-outcome-Measure	1214	1217	the
I-outcome-Measure	1218	1226	assigned
I-outcome-Measure	1227	1233	follow
I-outcome-Measure	1233	1234	-
I-outcome-Measure	1234	1236	up
I-outcome-Measure	1237	1241	care
I-outcome-Measure	1242	1245	and
I-outcome-Measure	1246	1251	unmet
I-outcome-Measure	1252	1257	needs
O	1257	1258	.

O	1259	1268	Secondary
O	1269	1277	outcomes
O	1278	1282	were
B-outcome-Measure	1283	1286	use
I-outcome-Measure	1287	1289	of
I-outcome-Measure	1290	1303	consultations
O	1303	1304	,
B-outcome-Measure	1305	1314	adherence
I-outcome-Measure	1315	1317	to
I-outcome-Measure	1318	1327	treatment
O	1328	1331	and
B-outcome-Measure	1332	1339	quality
I-outcome-Measure	1340	1342	of
I-outcome-Measure	1343	1347	life
O	1347	1348	.

O	1349	1356	Results
O	1356	1357	:
O	1358	1360	Of
O	1361	1364	the
B-total-participants	1365	1368	207
O	1369	1380	consecutive
O	1381	1389	patients
O	1390	1393	who
O	1394	1398	were
O	1399	1410	potentially
O	1411	1419	eligible
O	1420	1423	for
O	1424	1427	the
O	1428	1433	study
O	1433	1434	,
B-total-participants	1435	1438	134
O	1439	1444	women
O	1445	1449	were
O	1450	1458	enrolled
O	1459	1460	(
O	1460	1462	65
O	1462	1463	%
O	1463	1464	)
O	1464	1465	.

O	1466	1468	In
O	1469	1474	total
B-control-participants	1475	1477	64
O	1478	1483	women
O	1484	1486	in
O	1487	1495	standard
O	1496	1500	care
O	1501	1504	and
B-intervention-participants	1505	1507	60
O	1508	1513	women
O	1514	1516	in
O	1517	1531	individualized
O	1532	1536	care
O	1537	1541	were
O	1542	1550	analyzed
O	1550	1551	.

O	1552	1554	No
O	1555	1568	statistically
O	1569	1580	significant
O	1581	1592	differences
O	1593	1597	were
O	1598	1606	reported
O	1607	1609	in
O	1610	1618	relation
O	1619	1621	to
B-outcome	1622	1634	satisfaction
O	1634	1635	,
B-outcome	1636	1641	unmet
I-outcome	1642	1647	needs
O	1647	1648	,
B-outcome	1649	1658	adherence
I-outcome	1659	1661	to
I-outcome	1662	1671	treatment
O	1672	1674	or
B-outcome	1675	1682	quality
I-outcome	1683	1685	of
I-outcome	1686	1690	life
O	1690	1691	.

O	1692	1697	Women
O	1698	1700	in
O	1701	1709	standard
O	1710	1714	care
B-outcome	1715	1723	attended
I-outcome	1724	1729	twice
I-outcome	1730	1732	as
I-outcome	1733	1737	many
I-outcome	1738	1751	consultations
O	1752	1758	during
O	1759	1762	the
O	1763	1766	two
O	1767	1771	year
O	1772	1778	follow
O	1778	1779	-
O	1779	1781	up
O	1782	1788	period
O	1789	1791	as
O	1792	1797	women
O	1798	1800	in
O	1801	1815	individualized
O	1816	1820	care
O	1820	1821	;
B-iv-cont-mean	1822	1823	4
I-iv-cont-mean	1823	1824	.
I-iv-cont-mean	1824	1825	3
O	1826	1827	(
O	1827	1829	95
O	1829	1830	%
O	1831	1833	CI
O	1834	1835	3
O	1835	1836	.
O	1836	1837	9
O	1837	1838	-
O	1838	1839	4
O	1839	1840	.
O	1840	1841	7
O	1841	1842	)
O	1843	1849	versus
B-cv-cont-mean	1850	1851	2
I-cv-cont-mean	1851	1852	.
I-cv-cont-mean	1852	1853	1
O	1854	1855	(
O	1855	1857	95
O	1857	1858	%
O	1859	1861	CI
O	1861	1862	:
O	1863	1864	1
O	1864	1865	.
O	1865	1866	6
O	1866	1867	-
O	1867	1868	2
O	1868	1869	.
O	1869	1870	6
O	1870	1871	)
O	1871	1872	,
O	1873	1874	p
O	1875	1876	<
O	1877	1878	.
O	1878	1881	001
O	1881	1882	.

O	1883	1893	Conclusion
O	1893	1894	:
O	1895	1896	A
O	1897	1908	significant
O	1909	1918	reduction
O	1919	1921	in
O	1922	1935	consultations
O	1936	1939	was
O	1940	1948	observed
O	1949	1952	for
O	1953	1956	the
O	1957	1962	group
O	1963	1972	attending
O	1973	1987	individualized
O	1988	1992	care
O	1993	2000	without
O	2001	2013	compromising
O	2014	2017	the
O	2018	2026	patients
O	2026	2027	'
O	2028	2040	satisfaction
O	2040	2041	,
O	2042	2049	quality
O	2050	2052	of
O	2053	2057	life
O	2058	2060	or
O	2061	2070	adherence
O	2071	2073	to
O	2074	2083	treatment
O	2083	2084	.

O	2085	2088	For
O	2089	2092	the
O	2093	2101	majority
O	2102	2104	of
O	2105	2119	postmenopausal
O	2120	2125	women
O	2126	2133	treated
O	2134	2137	for
O	2138	2143	early
O	2144	2150	breast
O	2151	2157	cancer
O	2157	2158	,
O	2159	2173	implementation
O	2174	2176	of
O	2177	2182	ePROs
O	2183	2185	to
O	2186	2199	individualize
O	2200	2206	follow
O	2206	2207	-
O	2207	2209	up
O	2210	2214	care
O	2215	2218	was
O	2219	2227	feasible
O	2227	2228	.
